TABLE III.

Outcome Data^*

Postop. employment status (% [no.])
Employed full time	36% (9)
Student	4% (1)
Unemployed, seeking work	4% (1)
Retired	20% (5)
Unemployed, disabled	36% (9)
Reported daily prosthetic use (% [no./total no.])
Overall	76% (19/25)
Upper-extremity prosthetic use	40% (2/5)
Lower-extremity prosthetic use	85% (17/20)
Neuromodulator (NM) medication use (% [no./total no.])
NM use at latest follow-up	56% (14/25)
Successful discontinuation of NM use (use preceding TMR)	0% (5/5 continued)
New chronic NM use following amputation and TMR	45% (9/20)
Opioid medication use (% [no./total no.])
Opioid use at latest follow-up	16% (4/25)
Successful discontinuation of chronic opioid use (use preceding TMR)	50% (4/8 continued)
New chronic opioid use following amputation and TMR	0% (0/17)
RLP score†
Interference	8 (8-8) [32]
Intensity	4 (3-6) [10]
Behavior	7 (7-14.5) [33]
PLP score†
Interference	8 (8-8) [30]
Intensity	4 (3-5.5) [10]
Behavior	14 (7-16) [30]
Pain temporality (% [no./total no.])
No pain	48% (12/25)
Pain events without pain in between	44% (11/25)
Steady pain with slight changes	4% (1/25)
Steady pain with intense pain attacks	4% (1/25)

^*TMR = targeted muscle reinnervation, PLP = phantom limb pain, and RLP = residual limb pain.

^†The values are given as the median, with the interquartile range (IQR) in parentheses and the maximum in square brackets.